Interpreting Results

Understand Apollo clinical assessment scores and how to use them responsibly.
View as Markdown

Apollo results must be reviewed and interpreted by a qualified healthcare professional. They must not be communicated directly to patients without clinical review, and must not be used as a substitute for clinical judgement.

Results structure

1{
2 "results": {
3 "disorders": {
4 "depression": { "probability": 0.61, "severity": 0.58 },
5 "anxiety": { "probability": 0.47, "severity": 0.44 }
6 },
7 "symptoms": {
8 "depression": {
9 "anhedonia": {
10 "severity": 0.54,
11 "distribution": {
12 "none": 0.18, "mild": 0.31,
13 "moderate": 0.28, "severe": 0.23
14 }
15 }
16 },
17 "anxiety": {
18 "nervousness": {
19 "severity": 0.48,
20 "distribution": {
21 "none": 0.26, "mild": 0.28,
22 "moderate": 0.22, "severe": 0.24
23 }
24 }
25 }
26 }
27 }
28}

Disorder-level scores

ScoreDescription
probabilityLikelihood the patient meets the diagnostic threshold, expressed as a value between 0 and 1
severityOverall severity of the disorder if present, expressed as a value between 0 and 1
DisorderFieldClinical reference
Major depressiondepressionBenchmarked against PHQ-9 gold standard
Generalised anxiety disorderanxietyBenchmarked against GAD-7 gold standard
Probability rangeClinical indication
0.0 – 0.3Low likelihood — below diagnostic threshold
0.3 – 0.5Borderline — further assessment recommended
0.5 – 0.7Moderate likelihood — consistent with clinical presentation
0.7 – 1.0High likelihood — strongly consistent with diagnosis

Apollo probability scores are not diagnostic. They are intended to support clinical decision-making alongside other clinical information. Final diagnosis must be made by a qualified healthcare professional.

Symptom-level scores

FieldDescription
severityOverall severity of the symptom, expressed as a continuous value between 0 and 1
distributionEstimated probability across none, mild, moderate, severe categories. Values sum to 1.

Depression symptoms

SymptomField nameDSM-V criterion
AnhedoniaanhedoniaLoss of interest or pleasure
Low moodlowmoodDepressed mood
Sleep issuessleepissuesInsomnia or hypersomnia
Low energylowenergyFatigue or loss of energy
Appetite issuesappetiteissuesChanges in weight or appetite
Worthlessness / guiltworthlessnessissuesFeelings of worthlessness or excessive guilt
Concentration difficultiesconcentrationissuesDiminished ability to think or concentrate
Psychomotor changespsychomotorissuesPsychomotor agitation or retardation

Anxiety symptoms

SymptomField nameDSM-V criterion
NervousnessnervousnessFeeling nervous, anxious or on edge
Uncontrollable worryuncontrollableworryUnable to stop or control worrying
Excessive worryexcessiveworryWorrying too much about different things
Trouble relaxingtroublerelaxingTrouble relaxing
RestlessnessrestlessnessBeing so restless it is hard to sit still
IrritabilityirritabilityBecoming easily annoyed or irritable
DreaddreadFeeling afraid as if something awful might happen

Longitudinal monitoring

For efficacy measurement, we recommend establishing a baseline assessment before treatment begins and tracking changes at regular intervals.

Model version

1{
2 "model": "apollo-1.0"
3}

Results generated by different model versions should not be directly compared. thymia will notify integrators in advance of any model version changes. Contact support@thymia.ai for version change notifications.

Responsible use

Apollo is a regulated medical device. The following requirements apply to all clinical deployments:

  • Results must be reviewed by a qualified healthcare professional before any clinical action is taken.
  • Results must not be communicated directly to patients without clinical review.
  • Apollo must not be used as the sole basis for diagnosis or treatment decisions.
  • Apollo is not validated for use in emergency or crisis situations. If a patient is in crisis, follow your standard emergency protocols.

Next steps


Crown Commercial ServiceNHS DigitalISO 27001ISO 13485HIPAAGDPRCyber Essentials Certified